Skip to main content

Table 2 Cox Regression of PFS and OS from Start of First-Line Treatment by Treatment Regimen Group

From: Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study

 

HR

HR 95% CI

P Value

Progression Free Survival Parameters

 Treatment Group (N = 147)*

  

0.0115

  Reg B (N = 25) vs. Reg A (N = 66)

2.191

[1.294 - 3.710]

0.0035

  Reg C (N = 56) vs. Reg A (N = 66)

1.426

[0.926 - 2.197]

0.1070

 Age

0.991

[0.973 - 1.009]

0.3071

 Gender = Female (vs. Male)

0.990

[0.690 - 1.421]

0.9585

 Race Category = Minority (vs. White)

0.796

[0.456 - 1.389]

0.4224

 Body Mass Index

0.972

[0.935 - 1.010]

0.1517

 Geographic Region = South (vs. Non-South)

1.116

[0.747 - 1.668]

0.5927

 Insurance = Any Private (vs. No Private Insurance)

0.909

[0.611 - 1.352]

0.6383

 Known Stage IV at Diagnosis (vs. Early or Unknown Stage)

1.332

[0.815 - 2.179]

0.2530

 Performance Status = Impaired (vs. Unimpaired)

2.463

[1.431 - 4.239]

0.0011

 Brain Mets Present at Diagnosis (vs. Not)

1.111

[0.690 - 1.790]

0.6649

 Receipt of Radiation Therapy in the Advanced Setting = Yes (vs. No)

1.207

[0.726 - 2.005]

0.4685

 Smoking Status = Current (vs. Former/Never)

0.847

[0.539 - 1.330]

0.4710

 Weighted Comorbidity Index

1.038

[0.926 - 1.163]

0.5202

Overall Survival Analysis Parameters

 Treatment Group (N = 147)*

  

0.0040

  Reg B (N = 25) vs. Reg A (N = 66)

2.935

[1.528 - 5.635]

0.0012

  Reg C (N = 56) vs. Reg A (N = 66)

1.661

[1.035 - 2.665]

0.0354

 Age

0.995

[0.974 - 1.016]

0.6200

 Gender = Female (vs. Male)

0.641

[0.414 - 0.994]

0.0468

 Race Category = Minority (vs. White)

0.889

[0.490 - 1.613]

0.6998

 Body Mass Index

0.966

[0.924 - 1.010]

0.1276

 Known Stage IV at Diagnosis (vs. Early or Unknown Stage)

2.623

[1.422 - 4.838]

0.0020

 Performance Status = Impaired (vs. Unimpaired)

2.314

[1.331 - 4.024]

0.0029

 Brain Mets Present at Diagnosis (vs. Not)

1.343

[0.832 - 2.169]

0.2277

 Weighted Comorbidity Index

1.142

[1.008 - 1.293]

0.0369

  1. *Treatment group effects are reported in text as A vs. comparators (1/HR), but in this table with A as reference condition
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us